{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:50:49Z","timestamp":1789213849357,"version":"build-2803163510"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174040"],"award-info":[{"award-number":["82174040"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82405138"],"award-info":[{"award-number":["82405138"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005891","name":"National Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["zyyzdxk-2023060"],"award-info":[{"award-number":["zyyzdxk-2023060"]}],"id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019978","name":"Shanghai Pudong New Area Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019978","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015796","name":"Shanghai Lingjun Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015796","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.phrs.2026.108331","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:29:38Z","timestamp":1782851378000},"page":"108331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies"],"prefix":"10.1016","volume":"230","author":[{"given":"Xinyao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinmei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-1636","authenticated-orcid":false,"given":"Qin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108331_bib1","series-title":"World Health Organization","article-title":"WHO European regional obesity report 2022","author":"Organization","year":"2022"},{"key":"10.1016\/j.phrs.2026.108331_bib2","series-title":"World Obesity Atlas 2023","author":"Lobstein","year":"2023"},{"key":"10.1016\/j.phrs.2026.108331_bib3","first-page":"813","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","author":"Inbaraj","year":"2025","journal-title":"Glob. Reg. Natl. Preval. Adult Overweight Obes. 19902021 Forecasts 2050 a Forecast. Study Glob. Burd. Dis. Study 2021."},{"issue":"7","key":"10.1016\/j.phrs.2026.108331_bib4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/qjmed\/hcx152","article-title":"Complications of obesity","volume":"111","author":"Kinlen","year":"2018","journal-title":"QJM Int. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mcna.2017.08.012","article-title":"Maintenance of lost weight and long-term management of obesity","volume":"102","author":"Hall","year":"2018","journal-title":"Med. Clin. North. Am."},{"issue":"6","key":"10.1016\/j.phrs.2026.108331_bib6","doi-asserted-by":"crossref","first-page":"e1269","DOI":"10.1097\/SLA.0000000000003826","article-title":"Weight outcomes of sleeve gastrectomy and gastric bypass compared to nonsurgical treatment","volume":"274","author":"Arterburn","year":"2021","journal-title":"Ann. Surg."},{"key":"10.1016\/j.phrs.2026.108331_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f5934","article-title":"Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials","volume":"347","author":"Gloy","year":"2013","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.phrs.2026.108331_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41366-025-01729-1","article-title":"Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions","volume":"49","author":"Subramaniyan","year":"2025","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.phrs.2026.108331_bib9","article-title":"GLP\u2212 1 receptor agonists for the treatment of obesity: role as a promising approach","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.phrs.2026.108331_bib10","author":"ELa","year":"2026","journal-title":"ZEPBOUND (tirzepatide) Medicat. Guide"},{"key":"10.1016\/j.phrs.2026.108331_bib11","author":"Clinic","year":"2026","journal-title":"Phentermine (Oral. Route)"},{"key":"10.1016\/j.phrs.2026.108331_bib12","author":"Clinic","year":"2026","journal-title":"Naltrexone bupropion (Oral. Route)"},{"issue":"33","key":"10.1016\/j.phrs.2026.108331_bib13","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303696120","article-title":"Structural analysis of the dual agonism at GLP-1R and GCGR","volume":"120","author":"Li","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2026.108331_bib14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell. Metab."},{"key":"10.1016\/j.phrs.2026.108331_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"4","author":"Maselli","year":"2020","journal-title":"Diabetes Research Clinical Practice"},{"issue":"9","key":"10.1016\/j.phrs.2026.108331_bib16","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/dom.12506","article-title":"Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans","volume":"17","author":"van Bloemendaal","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2026.108331_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2026.108331_bib18","first-page":"949","article-title":"A case of severe cholestatic Hepatitis Induced by a Novel Dual Agonist of Glucagon-like Peptide-1 and glucose-dependent Insulinotropic polypeptide receptors","volume":"12","author":"Jiang","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/oby.23612","article-title":"Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program","volume":"31","author":"le Roux","year":"2023","journal-title":"Obesity"},{"issue":"3","key":"10.1016\/j.phrs.2026.108331_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108331_bib21","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"New. Engl. J. Med."},{"issue":"10402","key":"10.1016\/j.phrs.2026.108331_bib22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.phrs.2026.108331_bib23","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1111\/dom.16500","article-title":"Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial","volume":"27","author":"Yamauchi","year":"2025","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2026.108331_bib24","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.phrs.2026.108331_bib25","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1111\/dom.16463","article-title":"Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial","volume":"27","author":"Gibble","year":"2025","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.phrs.2026.108331_bib27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial","volume":"332","author":"Zhao","year":"2024","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.phrs.2026.108331_bib28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S2213-8587(24)00377-2","article-title":"Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"13","author":"Kadowaki","year":"2025","journal-title":"Lancet Diabetes & Endocrinol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108331_bib29","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/oby.24306","article-title":"Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN study","volume":"33","author":"Zhao","year":"2025","journal-title":"Obesity"},{"issue":"8","key":"10.1016\/j.phrs.2026.108331_bib30","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1111\/dom.16439","article-title":"Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial","volume":"27","author":"Zhao","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2026.108331_bib31","unstructured":"2024, M S. 2024 Tirzepatide-Bariatric Surgery 2024 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06721507."},{"key":"10.1016\/j.phrs.2026.108331_bib32","unstructured":"N. Skertich, 2024, Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss 2024 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06734273."},{"key":"10.1016\/j.phrs.2026.108331_bib33","unstructured":"2025, A.A. Bariatric Surgery vs. Semaglutide vs. Tirzepatide."},{"key":"10.1016\/j.phrs.2026.108331_bib34","unstructured":"Company. ELa. A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity. 2026 [Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06373146\u3009."},{"issue":"9","key":"10.1016\/j.phrs.2026.108331_bib35","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity\u2014a phase 2 trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"New. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108331_bib36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"Veniant","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.phrs.2026.108331_bib37","unstructured":"Amgen. Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-1) 2025 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06858839\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib38","unstructured":"Amgen. Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) 2025 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06858878\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib39","unstructured":"Amgen. Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease (MARITIME-3-J) 2025 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06987695\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib40","unstructured":"2026, Amgen. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF). 2026 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07037459."},{"key":"10.1016\/j.phrs.2026.108331_bib41","unstructured":"2025, Amgen. Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-1) 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07225686."},{"key":"10.1016\/j.phrs.2026.108331_bib42","unstructured":"2026, Amgen. Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy (MARITIME-OSA-2)."},{"key":"10.1016\/j.phrs.2026.108331_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/oby.70106","article-title":"Weekly Subcutaneous VK2735, a GIP\/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study","author":"Bays","year":"2026","journal-title":"Obesity"},{"key":"10.1016\/j.phrs.2026.108331_bib44","unstructured":"V. Therapeutics, 2025, Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity."},{"key":"10.1016\/j.phrs.2026.108331_bib45","unstructured":"Viking Therapeutics I. VK2735 for Weight Management Phase 3 (VANQUISH 1). 2025 [Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT07104500\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib46","unstructured":"I. Viking Therapeutics, 2026, VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2). 2026 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT07104383."},{"key":"10.1016\/j.phrs.2026.108331_bib47","unstructured":"Roche. [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1\/GIP receptor agonist CT-388 in people living with obesity. 2026 [Available from: \u3008https:\/\/www.roche.com\/media\/releases\/med-cor-2026-01-27\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib48","unstructured":"I. Carmot Therapeutics, 2024, A Study of CT-388 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity. 2024 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT06525935."},{"key":"10.1016\/j.phrs.2026.108331_bib49","unstructured":"I. Carmot Therapeutics, 2026, A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus. 2026 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT06628362."},{"issue":"2","key":"10.1016\/j.phrs.2026.108331_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13372","article-title":"The incretin\/glucagon system as a target for pharmacotherapy of obesity","volume":"23","author":"Del Prato","year":"2022","journal-title":"Obes. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib51","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/dc23-1287","article-title":"Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"47","author":"Zhang","year":"2024","journal-title":"Diabetes care"},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib52","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108331_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101063","article-title":"Mazdutide 9 mg in Chinese adults with a body mass index\u2265 30 kg\/m2 but without diabetes: a phase 2 randomized controlled trial","author":"Ji","year":"2026","journal-title":"Med"},{"issue":"22","key":"10.1016\/j.phrs.2026.108331_bib54","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in Chinese adults with obesity or overweight","volume":"392","author":"Ji","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108331_bib55","unstructured":"2025, Innovent Biologics. 2025 [Available from: https:\/\/www.innoventbio.com."},{"key":"10.1016\/j.phrs.2026.108331_bib56","unstructured":"2025, Ltd. IBSC, A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06884293."},{"key":"10.1016\/j.phrs.2026.108331_bib57","unstructured":"2025, Ltd. IBSC. A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI\u226528 kg\/m2. 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06931028."},{"key":"10.1016\/j.phrs.2026.108331_bib58","unstructured":"2025, Ltd. IBSC. A Study of IBI362 in Chinese Adolescents With Obesity or Overweight. 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07255209."},{"key":"10.1016\/j.phrs.2026.108331_bib59","unstructured":"2025, Hospital. BF. Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity. 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07135141."},{"issue":"7","key":"10.1016\/j.phrs.2026.108331_bib60","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/dom.14712","article-title":"Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease","volume":"24","author":"Parker","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2026.108331_bib61","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes care"},{"key":"10.1016\/j.phrs.2026.108331_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 456906: Discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","author":"Zimmermann","year":"2022","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2026.108331_bib63","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of glucagon","volume":"97","author":"M\u00fcller","year":"2017","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2026.108331_bib64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"New. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108331_bib65","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes & Endocrinol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108331_bib66","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose\u2013response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bl\u00fcher","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2026.108331_bib67","unstructured":"Ingelheim. B. A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight (SYNCHRONIZE\u2122-1) 2026 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06066515\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib68","unstructured":"Ingelheim. B. A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight (SYNCHRONIZE\u2122-2). 2026 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06066528\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib69","unstructured":"Ingelheim B. A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease (SYNCHRONIZE\u2122JP). 2025 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06176365\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib70","unstructured":"Ingelheim B. A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight. 2026 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06214741\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib71","unstructured":"Ingelheim B. A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity. 2025 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06745284\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib72","unstructured":"Nordisk N. Novo Nordisk's Amycretin Phase 2 Trial Demonstrates Significant Weight Loss and HbA1c Reduction in Patients with Type 2 Diabetes. 2025 [Available from: \u3008https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916463\u3009."},{"issue":"10499","key":"10.1016\/j.phrs.2026.108331_bib73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Gasiorek","year":"2025","journal-title":"Lancet"},{"issue":"10499","key":"10.1016\/j.phrs.2026.108331_bib74","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108331_bib75","unstructured":"N. Nordisk, 2024, A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes. 2024 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06542874."},{"key":"10.1016\/j.phrs.2026.108331_bib76","unstructured":"N. Nordisk, 2026, AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight. 2026 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07339423."},{"key":"10.1016\/j.phrs.2026.108331_bib77","unstructured":"NN. Novo Nordisk Advances Subcutaneous and Oral Amycretin into Phase 3 Development for Weight Management 2025 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07339423\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib78","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.phrs.2026.108331_bib79","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/db17-0480","article-title":"The gluco-and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.phrs.2026.108331_bib80","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/j.2040-4603.2021.tb00161.x","article-title":"Glucagon's metabolic action in health and disease","volume":"11","author":"Zeigerer","year":"2021","journal-title":"Compr. Physiol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108331_bib81","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"New. Engl. J. Med."},{"issue":"10401","key":"10.1016\/j.phrs.2026.108331_bib82","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.phrs.2026.108331_bib83","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S2213-8587(25)00092-0","article-title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","volume":"13","author":"Coskun","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2026.108331_bib84","unstructured":"2025, Company. ELa. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1). 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05929066."},{"key":"10.1016\/j.phrs.2026.108331_bib85","unstructured":"2025, Company. ELa. A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2). 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05929079."},{"key":"10.1016\/j.phrs.2026.108331_bib86","unstructured":"2025, Company. ELa. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3). 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05882045."},{"key":"10.1016\/j.phrs.2026.108331_bib87","unstructured":"2025, Company. ELa. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5). 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06662383."},{"key":"10.1016\/j.phrs.2026.108331_bib88","unstructured":"2025, Company. ELa. A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4). 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05931367."},{"key":"10.1016\/j.phrs.2026.108331_bib89","unstructured":"2025, Company. ELa. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7). 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07035093."},{"key":"10.1016\/j.phrs.2026.108331_bib90","unstructured":"2025, Company. ELa. A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity (TRIUMPH-6). 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06859268."},{"key":"10.1016\/j.phrs.2026.108331_bib91","unstructured":"2025, Company. ELa. A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8). 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07232719."},{"key":"10.1016\/j.phrs.2026.108331_bib92","unstructured":"N. Nordisk, 2026, Triple Receptor Agonist UBT251 Achieved 19.7% Mean Weight Reduction at 24 Weeks in Chinese Phase 2 Trial. 2026 [Available from: https:\/\/www.novonordisk.com.cn\/news---media\/2026022601.html."},{"key":"10.1016\/j.phrs.2026.108331_bib93","unstructured":"2025, The United Bio-Technology (Hengqin) Co. L. UBT251 Injection Phase II Study (Overweight or Obesity). 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07177469."},{"key":"10.1016\/j.phrs.2026.108331_bib94","unstructured":"2026, A\/S. NN. A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity. 2026 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07395687."},{"key":"10.1016\/j.phrs.2026.108331_bib95","unstructured":"2025, The United Bio-Technology (Hengqin) Co. L. UBT251 Injection Phase II Clinical Study (CKD). 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07134335."},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib96","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13098-023-00990-6","article-title":"SGLT2 inhibitor versus carbohydrate-restricted isocaloric diet: reprogramming substrate oxidation in type 2 diabetes","volume":"15","author":"Igarashi","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"issue":"45","key":"10.1016\/j.phrs.2026.108331_bib97","doi-asserted-by":"crossref","first-page":"26758","DOI":"10.1074\/jbc.270.45.26758","article-title":"Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y\/peptide YY Y2 receptor subtype","volume":"270","author":"Gerald","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108331_bib98","article-title":"The role of peptide YY in appetite regulation and obesity","author":"Karra","year":"2009","journal-title":"Wiley Online Libr."},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib99","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/dom.15984","article-title":"A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity","volume":"27","author":"Beetz","year":"2025","journal-title":"Diabetes Obes. Metab."},{"issue":"11_ement_1","key":"10.1016\/j.phrs.2026.108331_bib100","doi-asserted-by":"crossref","first-page":"s37","DOI":"10.1210\/jc.2008-1630","article-title":"Central control of body weight and appetite","volume":"93","author":"Woods","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.phrs.2026.108331_bib101","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/oby.24329","article-title":"Long-acting PYY3\u2212 36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies","volume":"33","author":"Wulff","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.phrs.2026.108331_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"bmj"},{"issue":"15","key":"10.1016\/j.phrs.2026.108331_bib103","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J. Med. Chem."},{"issue":"10403","key":"10.1016\/j.phrs.2026.108331_bib104","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b7 4 mg with once-weekly semaglutide 2\u00b7 4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.phrs.2026.108331_bib105","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"New. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2026.108331_bib106","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide\u2013semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108331_bib107","unstructured":"Nordisk N. A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2). 2026 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06065540\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib108","unstructured":"2026, A\/S NN. CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial 2026 [Available from: https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916481."},{"key":"10.1016\/j.phrs.2026.108331_bib109","unstructured":"2026, A\/S. NN. A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight. 2026 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06131437."},{"key":"10.1016\/j.phrs.2026.108331_bib110","unstructured":"2026, A\/S NN. CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved 2026 [Available from: https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916501&blog_tag=no-excerpt&blog_category=Medications+%2526+treatments%252CWeight+management."},{"key":"10.1016\/j.phrs.2026.108331_bib111","unstructured":"2026, A\/S. NN. REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels. 2026 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05669755."},{"key":"10.1016\/j.phrs.2026.108331_bib112","unstructured":"2025, A\/S. NN. A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight (REDEFINE 6). 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06323174."},{"key":"10.1016\/j.phrs.2026.108331_bib113","unstructured":"2024, NNAS. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise (REIMAGINE 1). 2024 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06323174."},{"key":"10.1016\/j.phrs.2026.108331_bib114","unstructured":"2025[Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06323161\u3009A\/S. NN. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin (REIMAGINE 3). 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06323161."},{"key":"10.1016\/j.phrs.2026.108331_bib115","unstructured":"A\/S. NN. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor. 2026 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06221969\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib116","unstructured":"2024, A\/S. NN. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both (REIMAGINE 5). 2024 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06534411."},{"key":"10.1016\/j.phrs.2026.108331_bib117","unstructured":"2025, A\/S. NN. A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity. 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06780449."},{"key":"10.1016\/j.phrs.2026.108331_bib118","unstructured":"2025, A\/S. NN. A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07011667."},{"key":"10.1016\/j.phrs.2026.108331_bib119","unstructured":"2024, A\/S. NN. A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight. 2024 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06388187."},{"key":"10.1016\/j.phrs.2026.108331_bib120","unstructured":"2025, A\/S. NN. A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight. 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07357766."},{"key":"10.1016\/j.phrs.2026.108331_bib121","unstructured":"2026, A\/S. NN. A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes. 2026 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07357740."},{"key":"10.1016\/j.phrs.2026.108331_bib122","unstructured":"A\/S. NN. A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes (REIMAGINEYOUNG). 2026 [Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07282613\u3009."},{"key":"10.1016\/j.phrs.2026.108331_bib123","unstructured":"2025, A\/S. NN. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight. 2025 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT07253285."},{"key":"10.1016\/j.phrs.2026.108331_bib124","unstructured":"N. Nordisk, 2026, A Study of How CagriSema Works on Appetite in People With Excess Body Weight. 2026 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06267092."},{"key":"10.1016\/j.phrs.2026.108331_bib125","unstructured":"N. Nordisk, 2025, Novo Nordisk Submits FDA Application for Once-Weekly GLP-1\/Amylin Combination CagriSema for Weight Management. 2025 [Available from: https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916470."},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib126","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12951-025-03112-8","article-title":"Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108331_bib127","first-page":"72","article-title":"Efficacy and safety of novel twincretin tirzepatide, a dual GIP\/GLP-1 receptor agonist, as an anti-obesity medicine in individuals without diabetes: a systematic review and meta-analysis","volume":"20","author":"Dutta","year":"2024","journal-title":"Touch. Endocrinol."},{"key":"10.1016\/j.phrs.2026.108331_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110669","article-title":"Perspectives in weight control in diabetes\u2013SGLT2 inhibitors and GLP-1\u2013glucagon dual agonism","volume":"199","author":"Iqbal","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.phrs.2026.108331_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2026.108331_bib130","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/13543784.2023.2283020","article-title":"Retatrutide showing promise in obesity (and type 2 diabetes)","volume":"32","author":"Doggrell","year":"2023","journal-title":"Expert. Opin. Investig. Drugs"},{"issue":"ement_1","key":"10.1016\/j.phrs.2026.108331_bib131","article-title":"1866-LB: A Phase 2 Study of Mazdutide 9 mg in Chinese Adults with BMI of 30 kg\/m2 or more","volume":"73","author":"Jiang","year":"2024","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.phrs.2026.108331_bib132","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes & Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib133","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad. Med."},{"issue":"8","key":"10.1016\/j.phrs.2026.108331_bib134","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/10600280211053867","article-title":"High-dose once-weekly semaglutide: a new option for obesity management","volume":"56","author":"Bradley","year":"2022","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.phrs.2026.108331_bib135","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00592-025-02611-2","article-title":"Muscle loss and GLP-1R agonists use","volume":"63","author":"Rossi","year":"2026","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.phrs.2026.108331_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108036","article-title":"Psychotropic effects of GLP-1R agonists","volume":"222","author":"Bucciarelli","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.108331_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156043","article-title":"Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis","volume":"161","author":"Lin","year":"2024","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib138","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon like peptide-1 receptor expression in the human thyroid gland","volume":"97","author":"Gier","year":"2012","journal-title":"J. Clin. Endocrinol. & Metab."},{"issue":"6","key":"10.1016\/j.phrs.2026.108331_bib139","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41571-026-01135-0","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown","volume":"23","author":"Mannucci","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108331_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100805","article-title":"The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity","volume":"6","author":"Scragg","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.phrs.2026.108331_bib141","article-title":"Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in Major Markets, Disease Overview and","author":"GlobalData","year":"2024","journal-title":"Drug. Forecast. 2033"},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib142","doi-asserted-by":"crossref","DOI":"10.1155\/jobe\/9919810","article-title":"Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon","volume":"2025","author":"Abdelrahman","year":"2025","journal-title":"J. Obes."},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib143","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12933-023-02101-1","article-title":"Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database","volume":"23","author":"Blin","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.phrs.2026.108331_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110625","article-title":"Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data","volume":"198","author":"Yang","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"10.1016\/j.phrs.2026.108331_bib145","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1161\/CIR.0000000000001258","article-title":"Forecasting the economic burden of cardiovascular disease and stroke in the United States through 2050: a presidential advisory from the American Heart Association","volume":"150","author":"Kazi","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2026.108331_bib146","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/13696998.2025.2459529","article-title":"Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes","volume":"28","author":"McEwan","year":"2025","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.phrs.2026.108331_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645507","article-title":"Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide","volume":"12","author":"Gallwitz","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108331_bib148","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s13300-020-00894-y","article-title":"A review on semaglutide: an oral glucagon-like peptide 1 receptor agonist in management of type 2 diabetes mellitus","volume":"11","author":"Kalra","year":"2020","journal-title":"Diabetes Ther."},{"issue":"10382","key":"10.1016\/j.phrs.2026.108331_bib149","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(22)02403-5","article-title":"Contemporary medical, device, and surgical therapies for obesity in adults","volume":"401","author":"Perdomo","year":"2023","journal-title":"Lancet"},{"issue":"D1","key":"10.1016\/j.phrs.2026.108331_bib150","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182600246X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182600246X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:33:53Z","timestamp":1786487633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182600246X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":150,"alternative-id":["S104366182600246X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108331","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108331"}}